| Q58227792 | A Novel Mechanism of Action for Angiotensin-(1–7) via the Angiotensin Type 1 Receptor |
| Q35545274 | AAV-based gene transfer |
| Q36445557 | Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery |
| Q40411990 | Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. |
| Q34429431 | Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor |
| Q40478824 | Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. |
| Q114231598 | Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective |
| Q38305480 | Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop |
| Q45875068 | Adenovirus serotype 5 hexon mediates liver gene transfer |
| Q38193206 | Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling |
| Q28565979 | Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor |
| Q28566391 | Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor |
| Q41401817 | Antagonists of GPR35 display high species ortholog selectivity and varying modes of action |
| Q64092404 | Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion |
| Q39342777 | Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses |
| Q34282191 | Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors |
| Q42261987 | Capsid modification strategies for detargeting adenoviral vectors |
| Q29397067 | Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2Novelty and Significance |
| Q35948498 | Cell-selective viral gene delivery vectors for the vasculature |
| Q39048039 | Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. |
| Q33440718 | Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum |
| Q33197377 | Development of efficient viral vectors selective for vascular smooth muscle cells |
| Q33286806 | Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. |
| Q40528748 | Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. |
| Q40528538 | Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats |
| Q39926337 | Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer |
| Q58227795 | Efficient Vascular Endothelial Gene Transfer Following Intravenous Adenovirus Delivery |
| Q38901143 | Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector |
| Q38502124 | Electrical consequences of cardiac myocyte: fibroblast coupling |
| Q40051540 | Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. |
| Q40431364 | Enhanced gene transfer activity of peptide-targeted gene-delivery vectors |
| Q42146790 | FX and host defense evasion tactics by adenovirus |
| Q38389922 | G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease |
| Q37122933 | G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation |
| Q39799967 | GPR35 as a Novel Therapeutic Target. |
| Q39097850 | Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction |
| Q29417122 | Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension |
| Q91714392 | Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo |
| Q37291653 | Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer |
| Q40822981 | Identification of peptides that target the endothelial cell-specific LOX-1 receptor. |
| Q38343485 | In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. |
| Q39502394 | Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors |
| Q41900381 | Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. |
| Q37284881 | Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. |
| Q35557004 | Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo |
| Q42805327 | Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting |
| Q40264847 | Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes |
| Q36842711 | Novel vectors for in vivo gene delivery to vascular tissue |
| Q46120246 | Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. |
| Q47420905 | Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts |
| Q38026374 | Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role? |
| Q35698680 | Promoters and control elements: designing expression cassettes for gene therapy. |
| Q38069197 | Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system |
| Q28475714 | Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X |
| Q38866016 | Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop |
| Q47613009 | Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction. |
| Q45876086 | Special focus issue on the annual meeting of the British Society for Gene and Cell Therapy |
| Q64947025 | Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. |
| Q31036743 | Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors |
| Q35095393 | Targeting gene therapy vectors to the vascular endothelium |
| Q42152828 | Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. |
| Q58227789 | The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice |
| Q37405405 | The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35 |
| Q58227799 | The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda |
| Q58227800 | The frequency of the haemochromatosis-associated genotype D6S265-1:D6S105-8 in blood donors |
| Q38230901 | The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery |
| Q36182171 | The influence of adenovirus fiber structure and function on vector development for gene therapy |
| Q37085147 | The relevance of coagulation factor X protection of adenoviruses in human sera. |
| Q34207550 | Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy |
| Q45870079 | Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q34791438 | Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy |
| Q33456433 | Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature |
| Q40655242 | Use of phage display to identify novel peptides for targeted gene therapy |
| Q58227790 | Utilizing proteomics to understand and define hypertension: where are we and where do we go? |
| Q33230629 | Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses |
| Q44631683 | Vector systems for prenatal gene therapy: principles of adenovirus design and production |